ARTICLE | Finance
Effector's expansion
Why Effector opted for a $40M B round to expand Ph I/II cancer trial
January 4, 2016 8:00 AM UTC
Effector Therapeutics Inc. had planned to complete a Phase I/II trial of eFT508 with existing cash, but preclinical data showing the compound's activity in a wide range of tumor types persuaded investors to back a $40 million B round to expand the trial.
Altitude Life Science Ventures led the round with participation from fellow new investors AbbVie Biotech Ventures and BioMed Ventures, as well as all of Effector's existing investors. ...